pulmonary disease – Page 36 – Communicable Diseases Research

Dual Substance Use of Electronic Cigarettes and Alcohol

Physiology

Published on 2020-11-022022-10-31
Journal: Frontiers in Physiology [Category] COVID-19,

Periodontal disease and targeted prevention using aMMP-8 point-of-care oral fluid analytics in the COVID-19 era

COVID-19 시대의 MMP-8 현장 진료 구강액 분석을 사용한 치주 질환 및 표적 예방

Article

Published on 2020-11-012022-09-11
Journal: Medical Hypotheses [Category] 바이오마커,

[키워드] Alzheimer's disease aMMP-8. approach approaches association Biomarker cardiovascular disease cardiovascular diseases Care Causality chronic obstructive chronic obstructive pulmonary disease complications COVID-19 COVID-19 infections CVD dentist Deterioration diabetes Diagnostic biomarkers disease ENhance equipment examination groups hands Health help hypertension hypothese hypotheses identify inflammatory disease multifactorial Non-invasive obstructive pulmonary disease oral health Patient periodontal periodontal disease Periodontitis point-of-care point-of-care technology point-of-care testing Potential potential biomarkers prevalent prevention professional pulmonary disease risk secondary prevention severe COVID-19 severe COVID-19 infections suggested Support systemic disease systemic diseases Teledentistry
[DOI] 10.1016/j.mehy.2020.110276 PMC 바로가기 [Article Type] Article

Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform

Articles

Published on 2020-11-012022-10-29
Journal: The Lancet. Respiratory Medicine [Category] COVID-19, Fulltext, SARS,

[키워드] 95% CI acute respiratory disease acute respiratory syndrome adjusted age analysed Analysis association Asthma calculated category chronic obstructive Cohort combination therapy COPD coronavirus covariates COVID-19 COVID-19 pandemic COVID-19-related death Cox regression model database death description diagnosed disease severity E-value EHR Electronic health record eligible England expected explained finding Follow-up funding hazard ratio Health high-dose ICS hospital HRs ICS ICSs increased risk individual Infection Inhaled inhaled corticosteroid LABA–LAMA LABA–LAMA combination long-acting muscarinic antagonist low-dose Medical Research Council medium dose Observational cohort study Observed office Older OpenSAFELY outcome Patient people with asthma people with COPD platform Prevalence primary care PROTECT pulmonary disease recorded respiratory medication SABA Sex short-acting β agonist smoker Statistics Support were given
[DOI] 10.1016/S2213-2600(20)30415-X PMC 바로가기 [Article Type] Articles

Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study

Observational Study

Published on 2020-11-012022-10-05
Journal: American journal of transplantation : official jou [Category] SARS, 임상,

Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab

리산키주맙으로 치료 중인 만성 폐쇄성 폐질환을 동반한 건선 환자의 코로나바이러스 질병 2019

Case Reports

Published on 2020-11-012022-09-11
Journal: Dermatologic therapy [Category] SARS, 진단, 치료제,

[키워드] chronic obstructive Coronavirus disease 2019 Patient pulmonary disease Treatment
[DOI] 10.1111/dth.14186 PMC 바로가기 [Article Type] Case Reports

The paradoxical effect of IL-6 and implications for the use of Tocilizumab in Covid-19 patients

IL-6의 역설적 효과와 코비드-19 환자에서 토실리주맙 사용에 대한 의미

Editorial

Published on 2020-11-012022-09-12
Journal: Medical Hypotheses [Category] B형 간염, 진단,

Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions

Review article

Published on 2020-11-012022-10-05
Journal: Pharmacological research [Category] 신약개발, 치료제,

[키워드] addition Admission ADRS Adverse drug reaction adverse event affected affecting antiviral agent bleeding cardiometabolic cardiometabolic diseases cardiovascular disease Cerebrovascular disease Chronic kidney disease chronic obstructive clinical monitoring Clinical outcome co-morbidity Comorbidity conducted contributing to Course COVID-19 COVID-19 disease COVID-19 infection COVID-19 patient COVID-19 patients death determine diabetes dose drug-drug interaction drugs evaluated extreme Hospitalization hypertension ICU increased risk Injury Interaction management medication Meta-analysis Mortality patients pharmacokinetic Potential potential risk pulmonary disease risk SARS-CoV-2 Severe infection Side-effect syndrome Time to recovery Treatment worsened worsening
[DOI] 10.1016/j.phrs.2020.105250 [Article Type] Review article

nSARS-Cov-2, pulmonary edema and thrombosis: possible molecular insights using miRNA-gene circuits in regulatory networks

Research

Published on 2020-10-302022-10-31
Journal: Exrna [Category] COVID-19,

[키워드] accompany Antigen presentation antigen-presentation approach Cell coronavirus 2 Diseases disorder drugs edema Factor Features Feed forward loops FFLs identify Infection Inflammatory response information loop miRNA miRNA coregulatory networks molecular molecular mechanism motif nSARS-CoV-2 pandemic pathophysiology pathway pulmonary disease Pulmonary edema regulate regulatory circuit regulatory network Research respiratory Result Signaling signaling pathway signaling pathways similarity Spread symptomatic targets TGF the disease thromboembolic thrombosis trajectory unique vaccine candidate viral replication virus virus spike protein while
[DOI] 10.1186/s41544-020-00057-y PMC 바로가기 [Article Type] Research

Practices and attitudes of bariatric surgeons in Israel during the first phase of the COVID-19 pandemic

Original Research Article

Published on 2020-10-302022-10-30
Journal: Israel Journal of Health Policy Research [Category] Coronavirus, MERS, SARS,

Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide

Cell Death & Injury

Published on 2020-10-302022-10-28
Journal: Bioscience Reports [Category] COVID-19, MERS, SARS,

[키워드] activated Activation ADP-ribose Aryl hydrocarbon receptor ATP biochemical Cancer caused cell death chronic obstructive clinical care component COPD Coronaviruses COVID-19 Critical cytokine determine drugs effective Efficacy ENhance enzyme event expression Gene Expression glucocorticoid Glucocorticoids HIV infection homologue Immunity Immunotherapy Indoleamine 2,3-dioxygenase induce information inhibit inhibitor intensive care Kynurenine pathway lung Lung injury NADP nicotinamide nuclear overexpressed PARP pathophysiology Patient patient mortality Poly (ADP-ribose) polymerase polymerase potent Prevent proinflammatory Proinflammatory cytokine pulmonary disease regulate Regulation respiratory syncytial virus RSV sequence silent sirtuin therapeutic use therapy Trial
[DOI] 10.1042/BSR20202856 PMC 바로가기 [Article Type] Cell Death & Injury